After the invention of a fusion drive made inter Solar System travel feasible, Earth and Mars emerged as the dominant superpowers, maintaining an uneasy political relationship with both each other and ...

Chugai Pharmaceutical Co., Ltd. announced that it has filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) for an additional indication of its anti-cancer agent/ALK ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer development. These genetic alterations result in the creation of hybrid genes with ...

ALK-Fusion Positive Lung Cancer ALK fusions occur in up to 5% of patients diagnosed with NSCLC. (10) Six tyrosine kinase inhibitors (TKIs) spanning three generations have been approved for ALK ...

“Our findings confirm that a RANBP2-ALK fusion can act as a driver mutation in AML and that gilteritinib can be a clinically effective and well-tolerated ALK inhibitor and could be considered as ...

Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.

In this special issue of CURE, we examine some of the latest developments in the treatment of ALK-positive non-small cell lung cancer (NSCLC). This subtype of lung cancer, representing about 5% of ...

PURPOSEIn GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non–small-cell lung cancer but may be important to offer personalized strategies of treatment ...

Most importantly, the KANK4-ALK fusion gene identified in this PACC was highly pathogenetic. Treatment with the ALK inhibitor alectinib obtained a radiologic partial response after 2 months of ...